Neuromyelitis Optica Spectrum Disorders

• CLINICAL_TRIALS trial_result · 2025-12-19
  Clinical Trial Update: Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD [Phase 3]

  Phase 3 clinical trial evaluating the efficacy, safety, pharmacokinetics, pharmacodynamics, and anti-drug antibodies of eculizumab in Chines…

• CLINICAL_TRIALS trial_result · 2025-09-10
  Clinical Trial Update: Evaluation of the Impact of Multiple Sclerosis and Its Treatments on Women Fertility

  This update summarizes a completed clinical trial evaluating the impact of multiple sclerosis and its treatments on women's fertility.

• CLINICAL_TRIALS trial_result · 2025-07-10
  Clinical Trial Update: A Phase I Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders [Phase 1]

  A Phase I trial evaluating BAT4406F injection in patients with Neuromyelitis Optica Spectrum Disorders has completed.

• CLINICAL_TRIALS trial_result · 2025-03-21
  Clinical Trial Update: BLAZE-Limiting Approach in NMOSD

  This clinical trial update notes the completed status of the BLAZE-Limiting Approach study in neuromyelitis optica spectrum disorders (NMOSD…

• CLINICAL_TRIALS trial_result · 2024-11-07
  Clinical Trial Update: Efficacy and Safety of Divozilimab in Patients With Neuromyelitis Optica Spectrum Disorders (AQUARELLE) [Phase 3]

  This document provides an update on a Phase 3 trial evaluating the efficacy and safety of Divozilimab in patients with Neuromyelitis Optica …

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2024-04-11
  Clinical Trial Update: A Longitudinal Study of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active NMOSD [Phase 1, Phase 2]

  A longitudinal Phase 1/2 trial evaluating ACTEMRA (tocilizumab) as monotherapy in highly active neuromyelitis optica spectrum disorders has …

• CLINICAL_TRIALS trial_result · 2024-01-18
  Clinical Trial Update: A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders [Phase 4]

  A Phase 4 clinical trial update for ineibilizumab in neuromyelitis optica spectrum disorders is in progress, with status currently unknown.

• CLINICAL_TRIALS trial_result · 2023-03-23
  Clinical Trial Update: An Open Label Study of the Effects of SHR1459 in NMOSDs Patients [Phase 2]

  Open-label Phase 2 trial assessing the effects of SHR1459 in patients with Neuromyelitis Optica Spectrum Disorders has completed.

• CLINICAL_TRIALS trial_result · 2019-12-26
  Clinical Trial Update: N-MOmentum: A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders [Phase 2, Phase 3]

  A completed Phase 2/3 clinical trial evaluating inebilizumab for Neuromyelitis Optica Spectrum Disorders.

• CLINICAL_TRIALS trial_result · 2019-10-24
  Clinical Trial Update: Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders [Phase 2, Phase 3]

  A Phase 2/3 trial comparing tocilizumab to azathioprine in neuromyelitis optica spectrum disorders (NMOSD) has completed.

• CLINICAL_TRIALS trial_result · 2018-10-17
  Clinical Trial Update: Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders [Phase 2]

  Phase 2 clinical trial evaluating autologous mesenchymal stem cells for neuromyelitis optica spectrum disorders (Devic's syndrome).